RCM
NKTR icon

Riverhead Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Riverhead Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$358K Buy
1,310
+173
+15% +$63.4K 0.01% 872
2019
Q2 		$607K Sell
1,137
-381
-25% -$191K 0.02% 655
2019
Q1 		$765K Sell
1,518
-3,591
-70% -$2.13M 0.03% 542
2018
Q4 		$2.52M Buy
5,109
+964
+23% +$582K 0.11% 240
2018
Q3 		$3.79M Buy
4,145
+3,669
+771% +$3.13M 0.14% 199
2018
Q2 		$348K Buy
476
+337
+242% +$389K 0.01% 830
2018
Q1 		$222K Sell
139
-673
-83% -$867K 0.01% 1015
2017
Q4 		$727K Buy
812
+140
+21% +$82.8K 0.03% 524
2017
Q3 		$242K Buy
672
+88
+15% +$27.5K 0.01% 899
2017
Q2 		$171K Buy
584
+257
+79% +$74.3K 0.01% 989
2017
Q1 		$115K Buy
327
+34
+12% +$7.64K 0.01% 939
2016
Q4 		$54K Hold
293
– – ﹤0.01% 1218
2016
Q3 		$76K Sell
293
-3,705
-93% -$954K ﹤0.01% 1015
2016
Q2 		$716K Buy
3,998
+2,121
+113% +$474K 0.02% 518
2016
Q1 		$387K Sell
1,877
-63
-3% -$12.1K 0.01% 988
2015
Q4 		$490K Buy
1,940
+1,333
+220% +$274K 0.01% 907
2015
Q3 		$100K Buy
+607
New +$107K ﹤0.01% 1088

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Riverhead Capital Management's NKTR Position: Q3 2019 in Review

Riverhead Capital Management increased its Nektar Therapeutics (NKTR) stake by 15% in Q3 2019, buying an estimated $63.4K and bringing the position to 1,310 shares worth $358K. The position accounts for 0.01% of the portfolio, ranked #872.

Riverhead Capital Management first reported a position in NKTR in Q3 2015 and has held it in 17 quarters since. The position peaked at $3.79M in Q3 2018. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • Riverhead Capital Management held 1,310 shares of Nektar Therapeutics worth $358K as of Q3 2019.
  • Riverhead Capital Management bought 173 Nektar Therapeutics shares in Q3 2019, an estimated $63.4K.
  • Nektar Therapeutics made up 0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #872 holding.
  • Riverhead Capital Management first reported a position in Nektar Therapeutics in Q3 2015 and has held it in 17 quarters since.
  • Riverhead Capital Management's Nektar Therapeutics position peaked at $3.79M in Q3 2018.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.